PL2068938T3 - Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI - Google Patents

Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI

Info

Publication number: PL2068938T3
Authority: PL; Poland
Prior art keywords: leukemia; tyrosine kinase; abl tyrosine; cmin; kinase inhibitor
Prior art date: 2006-09-22

Application number

PL07842842T

Other languages

English (en)

Inventor

Insa Gathmann

Francois-Xavier Mahon

Mathieu Molimard

Stéphane Picard

Yanfeng Wang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-22

Filing date

2007-09-20

Publication date

2011-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2068938(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-20 Application filed by Novartis Ag filed Critical Novartis Ag

2011-06-30 Publication of PL2068938T3 publication Critical patent/PL2068938T3/pl

Links

208000032839 leukemia Diseases 0.000 title abstract 4
239000005517 L01XE01 - Imatinib Substances 0.000 title abstract 2
229960002411 imatinib Drugs 0.000 title abstract 2
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title abstract 2
238000005457 optimization Methods 0.000 title 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title 1
229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
102000004441 bcr-abl Fusion Proteins Human genes 0.000 abstract 1
108010056708 bcr-abl Fusion Proteins Proteins 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
210000004214 philadelphia chromosome Anatomy 0.000 abstract 1
230000036470 plasma concentration Effects 0.000 abstract 1
230000035945 sensitivity Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Ecology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL07842842T 2006-09-22 2007-09-20 Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI PL2068938T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US82662206P	2006-09-22	2006-09-22
US82827806P	2006-10-05	2006-10-05
EP07842842A EP2068938B1 (en)	2006-09-22	2007-09-20	Optimization of the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitor imatinib
PCT/US2007/078978 WO2008036792A2 (en)	2006-09-22	2007-09-20	Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors

Publications (1)

Publication Number	Publication Date
PL2068938T3 true PL2068938T3 (pl)	2011-06-30

Family

ID=39092883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07842842T PL2068938T3 (pl)	2006-09-22	2007-09-20	Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI

Country Status (24)

Country	Link
US (2)	US20090281113A1 (pl)
EP (2)	EP2068938B1 (pl)
JP (1)	JP5735742B2 (pl)
KR (1)	KR20090065512A (pl)
AT (1)	ATE495761T1 (pl)
AU (1)	AU2007299764B2 (pl)
BR (1)	BRPI0717099A2 (pl)
CA (1)	CA2662977A1 (pl)
CL (1)	CL2007002725A1 (pl)
CY (1)	CY1111356T1 (pl)
DE (1)	DE602007012122D1 (pl)
DK (1)	DK2068938T3 (pl)
HR (1)	HRP20110250T1 (pl)
IL (1)	IL197296A (pl)
MA (1)	MA30786B1 (pl)
MX (1)	MX2009003082A (pl)
NO (1)	NO20091490L (pl)
NZ (1)	NZ575113A (pl)
PL (1)	PL2068938T3 (pl)
PT (1)	PT2068938E (pl)
TN (1)	TN2009000094A1 (pl)
TW (1)	TWI398251B (pl)
WO (1)	WO2008036792A2 (pl)
ZA (1)	ZA200901220B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2237783B1 (en) *	2008-01-23	2014-11-19	Novartis AG	Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib
JP2012510470A (ja) *	2008-12-01	2012-05-10	ノバルティスアーゲー	メシル酸イマチニブを用いたフィラデルフィア陽性白血病の処置を最適化する方法
US20110046919A1 (en)	2009-03-02	2011-02-24	Juliesta Elaine Sylvester	Method for accurate measurement of enzyme activities
FR2943418A1 (fr) *	2009-03-17	2010-09-24	Centre Nat Rech Scient	Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
EP3072964A1 (en) *	2013-11-22	2016-09-28	National Center For Child Health And Development	Novel chimera gene atf7ip-pdgfrb for acute lymphoblastic leukemia
JP6691558B2 (ja)	2015-07-07	2020-04-28	コデクシス，インコーポレイテッド	改善された活性を持つ新規のｐ４５０−ｂｍ３バリアント
IT201900008808A1 (it)	2019-06-13	2020-12-13	Univ Ca Foscari	Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) *	2022-06-28	2022-09-02	北京赛诺浦生物技术有限公司	一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521184A (en) *	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es)	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2366932C (en)	1999-04-15	2009-08-25	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
GB0202873D0 (en)	2002-02-07	2002-03-27	Novartis Ag	Organic compounds
EP1497463A1 (en) *	2002-04-17	2005-01-19	Novartis AG	Methods to predict patient responsiveness to tyrosine kinase inhibitors
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0222514D0 (en)	2002-09-27	2002-11-06	Novartis Ag	Organic compounds
MXPA06014247A (es)	2004-06-10	2007-03-12	Irm Llc	Compuestos y composiciones como inhibidores de la proteina quinasa.
GB0421525D0 (en)	2004-09-28	2004-10-27	Novartis Ag	Inhibitors of protein kineses
MY148074A (en)	2005-05-10	2013-02-28	Novartis Ag	Pharmaceutical compositions comprising imatinib and a release retardant

2007
- 2007-09-20 MX MX2009003082A patent/MX2009003082A/es active IP Right Grant
- 2007-09-20 BR BRPI0717099-8A patent/BRPI0717099A2/pt not_active IP Right Cessation
- 2007-09-20 AU AU2007299764A patent/AU2007299764B2/en not_active Ceased
- 2007-09-20 HR HR20110250T patent/HRP20110250T1/hr unknown
- 2007-09-20 US US12/442,126 patent/US20090281113A1/en not_active Abandoned
- 2007-09-20 DE DE602007012122T patent/DE602007012122D1/de active Active
- 2007-09-20 JP JP2009529384A patent/JP5735742B2/ja not_active Expired - Fee Related
- 2007-09-20 WO PCT/US2007/078978 patent/WO2008036792A2/en not_active Ceased
- 2007-09-20 NZ NZ575113A patent/NZ575113A/en not_active IP Right Cessation
- 2007-09-20 EP EP07842842A patent/EP2068938B1/en not_active Not-in-force
- 2007-09-20 KR KR1020097005757A patent/KR20090065512A/ko not_active Ceased
- 2007-09-20 AT AT07842842T patent/ATE495761T1/de active
- 2007-09-20 CA CA002662977A patent/CA2662977A1/en not_active Abandoned
- 2007-09-20 EP EP10171365A patent/EP2251042A3/en not_active Withdrawn
- 2007-09-20 DK DK07842842.2T patent/DK2068938T3/da active
- 2007-09-20 PT PT07842842T patent/PT2068938E/pt unknown
- 2007-09-20 PL PL07842842T patent/PL2068938T3/pl unknown
- 2007-09-21 TW TW096135633A patent/TWI398251B/zh not_active IP Right Cessation
- 2007-09-21 CL CL200702725A patent/CL2007002725A1/es unknown
2009
- 2009-02-20 ZA ZA2009/01220A patent/ZA200901220B/en unknown
- 2009-02-26 IL IL197296A patent/IL197296A/en not_active IP Right Cessation
- 2009-03-19 TN TN2009000094A patent/TN2009000094A1/fr unknown
- 2009-04-10 MA MA31775A patent/MA30786B1/fr unknown
- 2009-04-16 NO NO20091490A patent/NO20091490L/no not_active Application Discontinuation
2011
- 2011-03-23 CY CY20111100319T patent/CY1111356T1/el unknown
2016
- 2016-09-22 US US15/272,576 patent/US20170007605A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2007299764A1 (en)	2008-03-27
BRPI0717099A2 (pt)	2013-10-15
TW200822926A (en)	2008-06-01
JP2010504353A (ja)	2010-02-12
MX2009003082A (es)	2009-04-01
KR20090065512A (ko)	2009-06-22
WO2008036792A2 (en)	2008-03-27
EP2251042A3 (en)	2012-05-02
WO2008036792A3 (en)	2008-11-13
IL197296A0 (en)	2011-08-01
DE602007012122D1 (de)	2011-03-03
HK1133194A1 (en)	2010-03-19
AU2007299764B2 (en)	2011-10-13
MA30786B1 (fr)	2009-10-01
RU2009114856A (ru)	2010-10-27
ZA200901220B (en)	2010-02-24
US20170007605A1 (en)	2017-01-12
EP2251042A2 (en)	2010-11-17
JP5735742B2 (ja)	2015-06-17
NO20091490L (no)	2009-06-15
PT2068938E (pt)	2011-03-23
ATE495761T1 (de)	2011-02-15
CL2007002725A1 (es)	2008-05-16
HRP20110250T1 (hr)	2011-05-31
DK2068938T3 (da)	2011-04-04
CY1111356T1 (el)	2015-08-05
US20090281113A1 (en)	2009-11-12
CA2662977A1 (en)	2008-03-27
TWI398251B (zh)	2013-06-11
NZ575113A (en)	2012-03-30
EP2068938A2 (en)	2009-06-17
EP2068938B1 (en)	2011-01-19
IL197296A (en)	2011-11-30
TN2009000094A1 (en)	2010-08-19

Publication	Publication Date	Title
CY1111356T1 (el)	2015-08-05	Βελτιστοποιηση της θεραπειας της θετικης στο χρωμοσωμα της φιλαδελφειας λευχαιμιας με ιματινιμπη, εναν αναστολεα κινασης τυροσινης toy abl
Cappuzzo et al.	2003	Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
Pfingst et al.	2015	Importance of cochlear health for implant function
EA201400197A1 (ru)	2014-09-30	Имидазопиразиновые ингибиторы тирозинкиназы syk
Savastano et al.	2007	Antioxidant therapy in idiopathic tinnitus: preliminary outcomes
EP3552607A3 (en)	2020-01-15	Imidazopyrazine syk inhibitors
SG146653A1 (en)	2008-10-30	Methods and reagents for the treatment of immunoinflammatory disorders
KR20210137045A (ko)	2021-11-17	수면 개선 방법
DE602004026767D1 (de)	2010-06-02	Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen
Visser et al.	2013	Atypical vertical sound localization and sound-onset sensitivity in people with autism spectrum disorders
Hoyt et al.	2016	Sleep quality and depressive symptoms after prostate cancer: The mechanistic role of cortisol.
Scherer et al.	2009	Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents
Kokubun et al.	2007	Neurophysiological evaluation of trigeminal and facial nerves in patients with chronic inflammatory demyelinating polyneuropathy
Ko et al.	2015	Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats
BRPI0518795A2 (pt)	2008-12-09	mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
RU2010101634A (ru)	2011-07-27	Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi
DK1843757T3 (da)	2010-07-26	Behandling af fantomfænomener
WO2009061847A3 (en)	2009-12-30	Methods for diagnosing and treating pelvic pain disorders via beta-catenin
CN115175678B (zh)	2024-12-27	使用btk抑制剂及其组合治疗dlbcl的方法
WO2006023658A3 (en)	2009-04-02	Method of pre-selecting patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy
SG163614A1 (en)	2010-08-30	Colon cancer related gene tom34
RU2011122721A (ru)	2012-12-20	Способ оптимизации лечения хронического миелолейкоза ингибиторами тирозинказы abl
US20110224224A1 (en)	2011-09-15	Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate
TW200507828A (en)	2005-03-01	Method for treatment of chemotherapy-induced diarrhea
CN102526734A (zh)	2012-07-04	治疗年龄相关性听力损失的药物组合物及其应用